Table 3.
Logistic regression model to predict variables associated with treatment response based on RECIST or PET.
| RECIST (CR + PR) |
PET (metabolic response>50%) |
|||
|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | |
| Variables | ||||
| Age: >58 years (Ref:≦58 years) | 0.7 (0.2–2.2) | 0.51 | 0.7 (0.2–2.7) | 0.57 |
| Gender: female (Ref: male) | 0.1 (0.1–1.9) | 0.12 | 0.1 (0.1–5.1) | 0.89 |
| Smoking: yes (Ref: no) | 1.4 (0.2–10.8) | 0.75 | 4.8 (0.4–9.9) | 0.22 |
| Betel nut: yes (Ref: no) | 0.3 (0.1–1.8) | 0.18 | 0.3 (0.1–2.2) | 0.22 |
| P-16: positive (Ref: negative or unknown) | 1.1 (0.2–5.7) | 0.88 | 2.9 (0.3–6.1) | 0.48 |
| Primary cancer sites: others (Ref: oral cavity) | 2.0 (0.6–7.3) | 0.27 | 0.6 (0.1–3.0) | 0.57 |
| Original AJCC stage: IV (Ref: I-III) | 0.7 (0.2–3.1) | 0.65 | 0.4 (0.1–2.3) | 0.31 |
| Recurrent AJCC stage: rcIVb (Ref: rcIVa) | 2.7 (0.7–5.9) | 0.22 | 5.1 (0.3–3.2) | 0.27 |
| Re-irradiation interval: ≦12 months (Ref: >12 months) | 0.2 (0.1–0.6) | 0.006 | 0.1 (0.1–0.3) | 0.003 |
| SBRT sites: N or T + N (Ref: T) | 2.4 (0.6–9.5) | 0.21 | 3.8 (0.8–8.5) | 0.10 |
| SBRT dose: >40 Gy (Ref: 40 Gy) | 1.4 (0.4–4.9) | 0.57 | 4.9 (0.8–3.8) | 0.17 |
| Gross tumor volume: >50 ml (Ref:≦50 ml) | 0.6 (0.2–2.1) | 0.34 | 0.3 (0.1–1.1) | 0.17 |
| Acne formation: ≧grade 2 (Ref: grade 0–1) | 1.0 (0.2–4.4) | 0.99 | 0.7 (0.1–4.1) | 0.73 |
Abbreviations: RECIST: Response Evaluation Criteria in Solid Tumors; PET: positron emission tomography; OR: Odds ratio; CI: confidence interval; Ref: reference; SBRT: stereotactic body radiotherapy; T: gross tumor area; N: gross nodal area; SBRT: stereotactic body radiotherapy; AJCC: American Joint Committee on Cancer Staging System, 8th edition.